(Source: October 1; Stemedica Cell Technologies, Inc.)
Stemedica Cell Technologies, Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, was issued a new patent from the U.S. Patent & Trademark Office (USPTO), US 8,790,638 entitled “Composition of Stem Cells and Stem Cell Factors for Their Use and Manufacture.” This patent covers a method for treating patients with ischemic stroke, and the treatment includes intrathecal administration of hypoxically grown neural stem cells and intravenous administration of hypoxically grown mesenchymal stem cells.
“The issuance of this patent by the USPTO confirms a novel approach in the world of stem cell medicine – the simultaneous use of multiple stem cell lines to treat diseases,” says Stemedica’s President and Chief Medical Officer Nikolai Tankovich, M.D., Ph.D., FASLMS. “This combinatory approach targets various damaged tissues synergistically and uses different repair mechanisms that include, but are not limited to, treating a brain stroke from both sides of the blood-brain barrier. We believe that intravenous administration of Stemedica’s ischemia-tolerant mesenchymal stem cells (itMSCs) will help to release hundreds of repair proteins – the paracrine function of stem cells – to restore and build new vascularization and to improve the blood supply in tissues affected by stroke. Concurrently, via intrathecal administration, Stemedica’s ischemia-tolerant neural stem cells (itNSCs) will migrate to and replace damaged neurons, engraft into the brain’s neural network and produce neuromediators and electrical pulses to reconnect the damaged neural network and improve functionality of areas affected by the stroke.
“This patent presents a tremendous opportunity for Stemedica to introduce a new, combination method to treat patients suffering from the effects of ischemic stroke and to ameliorate their conditions,” says Stemedica’s Vice President of Intellectual Property Harris Brotman, J.D., Ph.D. “We hope our patented treatment methodology will alleviate the after-effects of ischemic strokes.”
Invented by Stemedica’s Chief Technology Officer Alex Kharazi, M.D., Ph.D., and Dr. Nikolai Tankovich, the new patent covers the treatment of stroke with two types of hypoxically grown stem cells, each with a different administration method. Stemedica’s itMSCs and itNSCs have obtained cGMP certification. itMSCs are currently being used in FDA-approved, Phase II clinical trials in the United States and internationally, and itNSCs are ready for clinical use beginning with Phase I-IIa safety studies.
Licensed by California’s Food and Drug Branch, Stemedica produces multiple adult, allogeneic stem cell lines grown under low-oxygen conditions (US Patent 8,420,394 entitled “Culturing Ectodermal Cells Under Reduced Oxygen Tension”), which is their natural environment in the body. Compared with cells grown under normoxic, or standard-oxygen conditions, in vitro experiments demonstrate that hypoxically grown cells show greater homing and engraftment, and they secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging and ischemic stroke. Stemedica’s products are also used by research institutions and hospitals for pre-clinical and clinical (human) trials. Under the auspices of the FDA and other international regulatory institutions, Stemedica is developing clinical trials for other indications using its adult, allogeneic stem cells. The company has headquarters in San Diego, California, and can be found online at www.stemedica.com. .
All media inquiries:
The Townsend Team